The trial is designed to assess MT-303 in adults with advanced or metastatic HCC that overexpresses GPC3. Credit: crystal light / Shutterstock.

Myeloid Therapeutics has dosed the first subject in a Phase I clinical trial of MT-303 for treating hepatocellular carcinoma (HCC).

The open-label, dose-escalation trial is designed to assess the pharmacokinetics, pharmacodynamics, safety and initial efficacy of MT-303 in adults with advanced or metastatic HCC that overexpresses GPC3.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This trial will also determine the recommended Phase II dose (RP2D) for MT-303.

An in vivo mRNA CAR programme of Myeloid, MT-303 is the second to enter clinical trials, advancing from their pipeline of in vivo immune cell programming therapies.

This candidate is a GPC3-FcA-LNP therapy and is claimed to have a robust preclinical profile that supported its progression into human trials.

GPC3 is highly expressed in most HCC tumours, with minimal expression in normal tissues, and its increased levels are associated with tumour growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In preclinical models of GPC3/HCC, MT-303 has shown effectiveness as a monotherapy, demonstrating its ability to combat tumours even without T cells.

The therapy also showed to express strongly in myeloid cells and had a favourable safety profile in rodents and non-human primates.

Compared with other treatments, MT-303 is said to have the potential to provoke a comprehensive immune response by presenting tumour neoantigens to activate T cells.

Myeloid chief medical officer Dr Matthew Maurer said: “We are thrilled to have swiftly advanced MT-303 into the clinic as the first in vivo CAR therapy applicable to the majority of liver cancers, and other cancers expressing GPC3.

“MT-303 can be administered like any other off-the-shelf intravenous therapy, without the need for pretreatment conditioning, and offers the potential to trigger a coordinated immune response against the cancer, reinforced and maintained with ongoing repeat dosing.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.